Properties and biological activities of thioredoxins

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 261-295

  Powis, G ^a   Montfort, W R ^a  

^a University of Arizona   (United States)

Author keywords

Thioredoxin reductase; Thioredoxin 1; Thioredoxin 2

Indexed keywords

THIOREDOXIN; THIOREDOXIN 1; THIOREDOXIN 2; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG STRUCTURE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TISSUE DISTRIBUTION; TUMOR GROWTH;

ANIMALS; ENZYME INHIBITORS; HUMANS; OXIDATION-REDUCTION; THIOREDOXIN; THIOREDOXIN REDUCTASE (NADPH);

MAMMALIA;

EID: 0035029131     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.261     Document Type: Review

References (232)

1. Enzymatic synthesis of deoxyribonucleotides VI. Isolation and characterization of thioredoxin, the hydrogen donor from Escherichia coli B
2. Thioredoxin
3. Redox regulation of cellular activation
4. Thioredoxins: Universal, yet specific thiol-disulfide redox cofactors
5. Athioredoxin-thioredoxin reductase system from rat tumor
6. Purification of thioredoxin from rat Novikoff ascites hepatoma
7. Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor
8. IL-2 receptor(p55)/TAC-inducing factor purification and characterization of adult T cell leukemia-derived factor
9. Identification of molecules involved in the 'early pregnancy factor' phenomenon
10. A genetic tool used to identify thioredoxin as a mediator of a growth inhibitory signal
11. The predicted amino acid sequence of human thioredoxin is identical to that of the autocrine growth factor human adult T-cell derived factor (ADF): Thioredoxin mRNA is elevated in some human tumors
12. Thioredoxin and glutaredoxin systems
13. Thioredoxin reductase
14. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene
15. Selenium and the thioredoxin redox system: Effects on cell growth and death
16. Regulation of human thioredoxin reductase expression and activity by 3′-untranslated region selenocysteine insertion sequence and mRNA instability elements
17. Rat and calf thioredoxin reductase are homologous to glutathione reductase with a carboxyl-terminal elongation containing a conserved catalytically active penultimate selenocysteine residue
18. Cloning and sequencing of human thioredoxin reductase
19. Cloning, sequencing and functional expression of a novel human thioredoxin reductase
20. Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver
21. Human mitochondrial thioredoxin reductase: cDNA cloning, expression and genomic organization
22. Structure of the mouse thioredoxin-encoding gene and its processed pseudogene
23. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism
24. 73> Ser mutation
25. Thioredoxin, a mediator of growth inhibition, maps to 9q31
26. Genomic cloning of human thioredoxin-encoding gene: Mapping of the transcription start point and analysis of the promoter
27. Isolation and characterization of human thioredoxin-encoding genes
28. Mouse thioredoxin gene maps on chromosome 4, whereas its pseudogene maps on chromosome 1
29. Cloning and expression of cDNA for human thioredoxin
30. + T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin
31. Alternative forms of the human thioredoxin mRNA: Identification and characterization
32. Absence of mutant forms of thioredoxin-1 (TRX-1) in human tumor cell lines and evidence for an alternatively spliced TRX-1 MRNA
33. Characterization of two thioredoxins in pig heart including a new mitochondrial protein
34. Cloning and expression of a novel mammalian thioredoxin
35. Molecular cloning and expression of a cDNA encoding a human thioredoxin-like protein
36. Purification, molecular cloning, and characterization of TRP32, a novel thioredoxin-related mammalian protein of 32 kDa
37. Cloning and characterization of the nucleoredoxin gene that encodes a novel nuclear protein related to thioredoxin
38. Human eosinophil cytotoxicity-enhancing factor II. Multiple forms synthesized by U937 cells and their relationship to thioredoxin/adult T cell leukemia-derived factor
39. Human eosinophil cytotoxicity-enhancing factor
40. The high-resolution three-dimensional solution structures of the oxidized and reduced state of human thioredoxin
41. Crystal structures of reduced, oxidized, and mutated human thioredoxins: Evidence for a regulatory homodimer
42. Crystal structure of thioredoxin from Escherichia coli at 1.68 Å resolution
43. Three-dimensional structure of Escherichia coli thioredoxin-S2 to 2.8 Å resolution
44. High-resolution solution structures of oxidized and reduced Escherichia coli thioredoxin
45. Structural and functional relations among thioredoxins of different species
46. Thioredoxin structure mechanism: Conformational changes on oxidation of the active-site sulfhydryls to a disulfide
47. On the reactivity and ionization of the active site cysteine residues of Escherichia coli thioredoxin
48. Mutagenesis of structural half-cystine residues in human thioredoxin and effects on the regulation of activity by selenodiglutathione
49. Human thioredoxin homodimers: Regulation of pH, role of Aspartate 60, and crystal structure of the Aspartate 60 > Asparagine mutant
50. Is human thioredoxin monomeric or dimeric?
51. Tissue distribution and subcellular localization of bovine thioredoxin determined by radioimmunoassay
52. Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF-kappaB
53. The solution structure of human thioredoxin complexed with its target from Ref-1 reveals peptide chain reversal
54. A novel promoter sequence is involved in the oxidative stress-induced expression of the adult T-cell leukemia derived factor (ADF)/human thioredoxin (Trx) gene
55. Transactivation of an inducible antioxidative stress protein, human thioredoxin by HTLV-I tax
56. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia
57. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment
58. Secretion of thioredoxin after in vitro activation of human B cells
59. Expression of thioredoxin and thioredoxin reductase in placentae of pregnant mice exposed to lipopolysaccharide
60. Hyperoxia induces thioredoxin and thioredoxin reductase gene expression in lungs of premature baboons with respiratory distress and bronchopulmonary dysplasia
61. Induction of thioredoxin and thioredoxin reductase gene expression in lungs of newborn primates by oxygen
62. Oxidoreductive regulation of nuclear factor kappa B
63. Induction of ADF/TRX by oxidative stress in keratinocytes and lymphoid cells
64. Increase in thioredoxin activity of intestinal epithelial cells mediated by oxidative stress
65. Mouse peroxiredoxin V is a thioredoxin peroxidase that inhibits p53-induced apoptosis
66. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide
67. Astroglial expression of ATL-derived factor, a human thioredoxin homologue, in the gerbil brain after transient global ischemia
68. Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma
69. Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavims DNA in neoplastic cervical squamous epithelium
70. Redox manipulation of DNA binding activity and BuGR epitope reactivity of the glucocorticoid receptor
71. Induction of thioredoxin in human lymphocytes with low-dose ionizing radiation
72. Thioredoxin is transcriptionally induced upon activation of heat shock factor 2
73. Thioredoxin gene expression is transcriptionally up-regulated by retinol in monkey conducting airway epithelial cells
74. Induction of thioredoxin, a redox-active protein, by ovarian steroid hormones during growth and differentiation of endometrial stromal cells in vitro
75. 17-betaestradiol induces protein thiol/disulfide oxidoreductases and protects cultured bovine aortic endothelial cells from oxidative stress
76. Regulation of thioredoxin mRNA in the rat uterus by gonadal steroids
77. Cell cycle inhibition of HTLV-1 transformed T cell lines by retinoic acid: The possible therapeutic use of thioredoxin reductase inhibitors
78. Thioredoxin a putative oncogene product is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival
79. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1
80. Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer
81. Enhanced coexpression of thioredixin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin
82. Direct association with thioredoxin allows redox regulation of glucocorticoid receptor function
83. Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: Their stabilization and redox signal-induced interaction with CBP/p300
84. Thioredoxin-dependent redox regulation of p53-mediated p21 activation
85. Nuclear transport factors: Function, behavior and interaction
86. Identification of a thioredoxin-related protein associated with plasma membranes
87. Detection of membrane associated thioredoxin on human cell lines
88. Adult Tcell leukemia-derived factor/Thioredoxin produced by both human T-lymphotropic virus type 1 and Epstein-Barr virustransformed lymphocytes, acts as an autocrine growth factor and synergized with interleukin-1 and interleukin-2
89. Secretion of thioredoxin after in vitro activation of human B cells
90. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway
91. Neuroprotection by glial cells through adult T cell leukemia-derived factor/human thioredoxin (ADF/TRX)
92. High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells
93. Interleukin Iβ and thioredoxin are secreted through a novel pathway of secretion
94. Site-directed mutagenesis of active site cysteines in human thioredoxin produces competitive inhibitors of human thioredoxin reductase and elimination of mitogenic properties of thioredoxin
95. ATL-derived factor (ADF) an IL-2 receptor/Tac inducer homologous to thioredoxin: Possible involvement of dithiol-reduction in the IL-2 receptor induction
96. Thioredoxin as a potent costimulus of cytokine expression
97. Involvement of thioredoxin in rheumatoid arthritis: Its costimulatory roles in the TNF-alpha-induced production of IL-6 and IL-8 from cultured synovial fibroblasts
98. Thioredoxin negatively regulates p38 MAP kinase activation and IL-6 production by tumor necrosis factor-alpha
99. cdc2 kinase activation in mouse two-cell block
100. 2 upon thioredoxin-enriched lens epithelial cells
101. The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase
102. The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine
103. Influence of treatment with aminoglutethimide on plasma and red-bloodcell glutathione status in breast cancer patients
104. Recent trends in glutathione biochemistry glutathione-protein interactions: A molecular link between oxidative stress and cell proliferation?
105. Thioredoxin-dependent peroxide reductase from yeast
106. Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation
107. Cloning and sequence analysis of candidate human nautral killer-enhancing factor genes
108. Localization of TDPX1, a human homologue of the yeast thioredoxin-dependent peroxide reductase gene (TPX) to chromosome 13q12
109. A human cDNA corresponding to a gene overexpressed during cell proliferation encodes a product sharing homology with amoebic and bacterial proteins
110. Crystal structure of a multifunctional 2-Cys peroxiredoxin heme-binding protein 23 kDa/proliferation-associated gene product
111. Mammalian peroxidoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factorα
112. Purification and characterization of a substrate protein for mitochondrial ATP-dependent protease in bove adrenal cortex
113. Cloning of the peroxiredoxin gene family in rats and characterization of the, fourth member
114. Cutting edge: TRANK, a novel cytokine that activates NF-kappaB and c-Jun N-terminal kinase
115. Charaterization of a mammaliam peroxiredoxin that contains one conserved cysteine
116. Genetic mapping of six mouse peroxiredoxin genes and fourteen peroxiredoxin related sequences
117. Peroxiredoxin I expression in human thyroid tumors
118. Murine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to hypoxic and ischemic injury
119. Identification of a natural killer enhancing factor (NKEF) from human erythroid cells
120. Endogenous natural killer enhancing factor-B increases cellular resistance to oxidative stresses
121. Organization and chromosomal assignment of two human PAG gene loci: PAGA encoding a functional gene and PAGB a processed pseudogene
122. Thioredoxin peroxidase is a novel inhibitor of apoptosis with a mechanism distinct from that of Bcl-2
123. Overexpression of thioredoxin in fanconi anemia fibroblasts prevents the cytotoxic and DNA damaging effect of mitomycin C and diepoxybutane
124. The pag gene product, a physiological inhibitor of c-abl tyrosine kinase is overexpressed in cells entering S phase and by contact with agents inducing oxidative stress
125. Selenocysteine
126. Effect of selenium on rat thioredoxin reductase activity: Increase by supranutritional selenium and decrease by selenium deficiency
127. Ribonucleotide reductases
128. Properties of a thioredoxin purified from rabbit bone marrow which fails to serve as a hydrogen donor for the homologous ribonucleotide reductase
129. Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin
130. Reduced thioredoxin: A possible physiological cofactor for vitamin K epoxide reductase. Further support for an active site disulfide
131. Stimulation of the dithiol-dependent reductases in the vitamin K cycle by the thioredoxin system: Strong synergistic effects with protein disulphideisomerase
132. Is thioredoxin the physiological vitamin K epoxide reducing agent?
133. Rel/NF-kappaB/IkappaB proteins and cancer
134. Expression of the v-rel oncogene in reticuloendotheliosis virus-transformed fibroblasts
135. Modulation of transcription factor NF-kappaB binding activity by oxidation-reduction in vitro
136. Oxidoreductive regulation of nuclear factor kappaB: Involvement of a cellular reducing catalyst thioredoxin
137. Distinct effects of glutathione disulfide on the nuclear transcription factors kappaB and the activator protein-1
138. Induction and function of FcERII on YT cells: Possible role of ADF/thioredoxin in FcERII expression
139. Thioredoxin regulates the DNA binding activity of NF-kappaB by reduction of a disulphide bond involving cysteine 62
140. The structure of NFkappaB p50 homodimer bound to a kappaB site
141. Structure of the NF-kappaB homodimer bound to DNA
142. NF-kappaB transactivation is increased but not involved in the proliferative effects of thioredoxin overexpression in MCF-7 breast cancer cells
143. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-kappaB and AP-1
144. Role of cysteines 640, 656, and 661 in steroid binding to rat glucocorticoid receptors
145. Thioredoxin: A redox-regulating cellular co-factor for glucocorticoid hormone action. Cross talk between endocrine control of stress response and cellular antioxidant defense system
146. Evidence that the endogenous heat-stable glucocorticoid receptor-activating factor is thioredoxin
147. Thioredoxin in the endocrine response to stress
148. 2 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor
149. Redox regulation of fos and jun DNA-binding activity in vitro
150. The redox and DNA-repair activities of ref-1 are encoded by nonoverlapping domains
151. Redox modulation of AP-2 DNA binding activity in vitro
152. Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator
153. Redox regulation of the DNA binding activity in transcription factor PEBP2. The roles of two conserved cysteine residues
154. p53 and human cancers
155. Enhanced phosphorylation of p53 by ATM in response to DNA damage
156. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
157. Redox modulation of p53 conformation and sequnce-specific DNA binding in vitro
158. Human p53 inhibits growth in Schizosaccharomyces pombe
159. A mutation in a thioredoxin reductase homolog suppresses p53-induced growth inhibition in the fission yeast Schizosaccharomyces pombe
160. Deletion of the Saccharomyces cerevisiae TRR1 gene encoding thioredoxin reductase inhibits p53-dependent reporter gene expression
161. The human 53 negative regulatory domain mediates inhibition of reporter gene transactivation in yeast lacking thioredoxin reductase
162. Identification of redox/repair protein Ref-1 as a potent activator of p53
163. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1
164. Activation of apoptosis signal-regulating kinase 1 (ASK1) by tumor necrosis factor receptor-associated factor 2 requires prior dissociation of the ASK1 inhibitor thioredoxin
165. Human thioredoxin attenuates hypoxia-reoxygenation injury of murine endothelial cells in a thiol-free condition
166. Demonstration of the interaction of thioredoxin with p40phox, a phagocyte oxidase component, using a yeast two-hybrid system
167. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways
168. Molecular cloning and characterization of the mouse apoptosis signal-regulating kinase 1
169. Proteolytic activation of MST/Krs, STE20-related protein kinase, by caspase during apoptosis
170. Adult T cell leukemia (ATL)-derived factor/human thioredoxin prevents apoptosis of lymphoid cells induced by L-cystine and glutathione depletion: Possible involvement of thiol-mediated redox regulation in apoptosis caused by pro-oxidant state
171. Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells
172. Thioredoxin, a gene found overexpressed in human cancer, inhihitis apoptosis in vitro and in vivo
173. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14:18)
174. The role of thioredoxin in filamentous phage assembly. Construction, isolation, and characterization of mutant thioredoxins
175. Interaction of mutant thioredoxin of Escherichia coli with the gene 5 protein of phage T7: The redox capacity of thioredoxin is not required for stimulation of DNA polymerase activity
176. Site-directed mutagenesis of human thioredoxin. Identification of cysteine 74 as critical to its function in the "early pregnancy factor" system
177. Possible roles of an adult T-cell leukemia (ATL)-derived factor/thioredoxin in the drug resistance of ATL to adriamycin
178. Cell linedirected screening assay for inhibitors of thioredoxin reductase signalling as potential anticancer drugs
179. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin and etoposide
180. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines
181. Overexpression of thioredoxin does not confer resistance to cisplatin in transfected human ovarian and colon cancer cell lines
182. Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): Protective effect of human thioredoxin against CDDP-induced cytotoxicity
183. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II)
184. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma
185. Protection against repeffusion-induced arrhythmias by human thioredoxin
186. Effect of recombinant human adult T cell leukemia-derived factor on rat lung reperfusion injury
187. Amelioration of ischemia-reperfusion injury by human thioredoxin in rabbit lung
188. Inhibition of reperfusion injury by human thioredoxin (adult T-cell leukemia-derived factor) in canine lung transplantation
189. Expression and distribution of redox regulatory protein, thioredoxin during transient focal brain ischemia in the rat
190. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage
191. Protective effect of adult T-cell leukemia-derived factor on retinal ischemica-reperfusion injury in the rat
192. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene
193. Immunohistochemical localization of adult T-cell leukaemia-derived factor, a human thioredoxin homologue, in human fetal tissues
194. Pancreati beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes
195. Comparison of the activities of protein disulphide-isomerase and thioredoxin in catalyxing disulphide isomerization in a protein substrate
196. Thioredoxin regenerates proteins inactivated by oxidative stress in endothelial cells
197. m iodothyronine 5′-deiodinase
198. Involvement of thiol transferase- and thioredoxin-dependent systems in the protection of 'essential' thiol groups of ornithine decarboxylase
199. Protein disulphide isomerase: Building bridges in protein folding
200. Evidence for a novel thioredoxin-like catalytic property of gonadotropic hormones
201. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells
202. Elevation of plasma thioredoxin levels in HIV infected individuals
203. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery
204. Detection of thioredoxin in human serum and biological samples using a sensitive sandwich ELISA with digoxigenin-labeled antibody
205. Sensitive enyme-linked immunosorbent assay for adult T-cell leukemia-derived factor and normal value measurement
206. ADF/thioredoxin as an indicator of oxidative stress
207. Immunohistochemical distribution of adult T-cell leukemia-derived factor/thioredoxin in epithelial components of normal and pathologic human skin conditions
208. Superoxide and peroxynitrite in atherosclerosis
209. Nitric oxide-induced inhibition of lung endothelial cell nitric oxide synthase via interaction with allosteric thiols: Role of thioredoxin in regulation of catalytic activity
210. Thioredoxin overexpression prevents NO-induced reduction of NO synthase activity in lung endothelial cells
211. Expression of thioredoxin is enhanced in atherosclerotic plaques and during neointima formation in rat arteries
212. Early pregnancy factor: Biology and clinical significance
213. Regulation of eosinophil migration by adult T cell leukemia-derived factor
214. Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: Involvement of dithiol related reduction
215. Role of ADF/TRX and its inhibitor on the release of major basic protein from human eosinophils
216. Increased expression of human thioredoxin/adult T cell leukemia-derived factor in Sjogren's syndrome
217. Decreased thioredoxin and increased thioredoxin reductase levels in alzheimer's disease brain
218. Dysregulation of adult T-cell leukemia-derived factor (ADF)/thioredoxin in HIV infection: Loss of ADF high-producer cells in lymphoid tissues of AIDS patients
219. Opposing regulatory effects of thioredoxin and eosinophil cytotoxicity-enhancing factor on the development of human immunodeficiency virus 1
220. Increased expression of thioredoxin in human primary and metastatic colon cancer
221. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues
222. Thioredoxin redox signalling: A novel target for anticancer drug development
223. Two sulphonated dye compounds which compete for inosital 1,4,5-trisphosphate binding to rat liver microsomes: Effects on 5′-phosphatase activity
224. Protection against toxic effects of formaldehyde in vitro, and of methanol or formaldehyde in vivo, by subsequent administration of SH reagents
225. Increased NADPH: (quinone-acceptor) oxidoreductase (DT-diaphorase) activity is associated with density dependent growth inhibition of normal but not transformed cells
226. Phage display identifies thioredoxin and superoxide dismutase as novel protein kinase C-interacting proteins: Thioredoxin inhibits protein kinase C-mediated phosphorylation of histone
227. Identification of thioredoxin-binding protein-2/vitamin D (3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression
228. Phage display reveals a novel inter-action of human tear lipocalin and thioredoxin which is relevant for ligand binding